EichorEICHOR
Study identifier: NCT02453282 Synced from ClinicalTrials.gov · August 06, 2026
● Study status: Active Not Recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Condition: Non-Small-Cell Lung Carcinoma NSCLC  ·  Sponsor: AstraZeneca

PhasePhase 3
Planned participants1118
Who can joinAll sexes, 18 Years to 130 Years
Healthy volunteersNo

About this study

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (196)

Research SiteScottsdale, Arizona, United States—
Research SiteTucson, Arizona, United States—
Research SiteYuma, Arizona, United States—
Research SiteBakersfield, California, United States—
Research SiteFullerton, California, United States—
Research SiteLa Jolla, California, United States—
Research SiteLos Angeles, California, United States—
Research SiteLos Angeles, California, United States—
Research SiteRedondo Beach, California, United States—
Research SiteSacramento, California, United States—
Research SiteSan Luis Obispo, California, United States—
Research SiteSanta Maria, California, United States—

+ 184 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02453282